AbbVie Inc (ABBV)vsDoximity Inc (DOCS)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
DOCS
Doximity Inc
$24.20
-1.51%
HEALTHCARE · Cap: $4.56B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 9490% more annual revenue ($61.16B vs $637.78M). DOCS leads profitability with a 37.5% profit margin vs 6.9%. ABBV appears more attractively valued with a PEG of 0.48. DOCS earns a higher WallStSmart Score of 66/100 (B-).
ABBV
Buy63
out of 100
Grade: C+
DOCS
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+45.2%
Fair Value
$47.37
Current Price
$24.20
$23.17 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Keeps 38 of every $100 in revenue as profit
Strong operational efficiency at 38.9%
Safe zone — low bankruptcy risk
Every $100 of equity generates 24 in profit
Growing faster than its price suggests
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Earnings declined 16.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : DOCS
The strongest argument for DOCS centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 37.5% and operating margin at 38.9%. PEG of 0.67 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : DOCS
The primary concerns for DOCS are EPS Growth.
Key Dynamics to Monitor
ABBV profiles as a value stock while DOCS is a mature play — different risk/reward profiles.
DOCS carries more volatility with a beta of 1.42 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
DOCS scores higher overall (66/100 vs 63/100), backed by strong 37.5% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Doximity Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Doximity, Inc. (Ticker: DOCS) is a U.S. healthcare technology company that operates a digital platform tailored for medical professionals. The company’s cloud-based network provides secure communication and collaboration tools, telemedicine services, clinical workflow solutions, and access to medical news, research, and career-management features for physicians, nurse practitioners, physician assistants, and other clinicians. Headquartered in San Francisco, California, Doximity’s Class A common stock trades on the New York Stock Exchange under the ticker DOCS.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?